Bill > S909

This bill aims to significantly lower prescription drug prices in the United States by ending government-granted monopolies for manufacturers who charge drug prices that are higher than the median prices in five reference countries (Canada, the United Kingdom, Germany, France, and Japan). The Secretary of Health and Human Services will establish a process to review brand name drug prices annually and determine if the price is excessive based on international reference prices or other factors. If a drug is deemed to have an excessive price, the government-granted exclusivities will be waived, and open, non-exclusive licenses will be granted to allow any person to manufacture and sell the drug. The bill also requires drug manufacturers to report detailed pricing and cost information, and prohibits anticompetitive behavior that could interfere with the implementation of the bill's provisions.

Health and Social Services

https://www.congress.gov/bill/117th-congress/senate-bill/909/all-info